Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Popular for:Cognitive enhancement, synaptogenesis, HGF/c-Met agonist
0
Registered Trials
0
Trial Publications
17
PubMed References
Animal
Evidence Level
Overview
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide analog of angiotensin IV developed at Washington State University. The short version: people usually care about it for cognitive enhancement, synaptogenesis, hgf/c-met agonist, but the strength of the evidence depends heavily on indication and study type.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide analog of angiotensin IV developed at Washington State University. It is one of the most potent cognitive-enhancing compounds identified in research, reported to be approximately 10 million times more potent than BDNF at promoting synaptic connectivity.
Dihexa was designed as a stable, orally bioavailable hepatocyte growth factor (HGF) receptor agonist. Research has focused on its potential for treating cognitive deficits associated with Alzheimer's disease and age-related cognitive decline, primarily in animal models.
Research Snapshot
What the evidence says
AnimalDihexa currently shows 0 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 17 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 0 registered trials are tracked from ClinicalTrials.gov intervention records.
- 0 PubMed clinical-trial publications are indexed.
- 0 PubMed randomized controlled trial publications are indexed.
- 17 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Dihexa acts as a potent agonist of the hepatocyte growth factor (HGF) / c-Met receptor system in the brain.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
0
Registered Trials
0
Trial Publications
0
RCT Publications
17
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
0
Registered trials
0
Trial publications
0
RCT publications
17
PubMed references
4
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
Dihexa
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceNot FDA-approved. Pre-clinical research compound. Developed at Washington State University. No human clinical trials. The HGF/c-Met pathway has oncogenic implications that require careful evaluation.
Key PubMed References
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.
Wells RG, Azzam AF, Hiller AL, et al. · Journal of Huntington's disease · 2024
PMID: 38489193Efficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy.
Pan T, Wang N, Zhang J, et al. · Stem cell research & therapy · 2022
PMID: 35410439Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies.
Weiss JB, Phillips CJ, Malin EW, et al. · Annals of medicine and surgery (2012) · 2021
PMID: 34703584AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.
Sun X, Deng Y, Fu X, et al. · Brain sciences · 2021
PMID: 34827486Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for Dihexa yet.
Side Effects & Safety
- Very limited safety data (primarily animal research) - Potential oncogenic concerns (HGF/c-Met pathway involved in cancer) - Long-term effects unknown - No human clinical trials completed
Known Interactions
No curated interaction entry is live for Dihexa yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.